Dana-Farber Clinical Leadership
Craig A. Bunnell, MD, MPH, MBA
Chief Medical Officer
Craig A. Bunnell, MD, MPH, MBA, is the Morse Family Chief Medical Officer at Dana-Farber. Under his leadership, the Institute has become a pioneer in implementing technology to enhance patient flow, operational efficiency, and patient access. He is also a breast medical oncologist in the Susan F. Smith Center for Women’s Cancers, and an Associate Professor of Medicine at Harvard Medical School, where he also earned his MD.
Bunnell holds, or has held, leadership positions at the National Comprehensive Cancer Centers, American Society of Clinical Oncology, Association of American Cancer Institutes, Massachusetts Society of Clinical Oncology, and the American Cancer Society. In 2010, he was named Boston Business Journal's Champion in Healthcare for Industry Innovation. Bunnell received his MPH from the Harvard School of Public Health and his MBA from the Massachusetts Institute of Technology. He completed his medical training at Brigham and Women's Hospital, where he also served as Chief Medical Resident.
Anne Gross, PhD, RN, NEA-BC, FAAN
Senior Vice President, Patient Care Services and Chief Nursing Officer
Anne Gross, PhD, RN, NEA-BC, FAAN, became Dana-Farber's Senior Vice President for Patient Care Services and Chief Nursing Officer in 2016. Gross joined Dana-Farber in 2002 and has served as Vice President, Adult Nursing and Clinical Services since 2004. She also holds the inaugural Ning Zhao Chair of Nursing.
Gross is a fellow of the American Academy of Nursing and serves as co-chair elect of the Academy’s Fellows Selection Committee. Prior to joining Dana-Farber, she was a clinical nurse and leader, most recently at Cambridge Health Alliance. She received her bachelor’s degree in nursing from St. Louis University, her master’s degree in nursing from Boston College, and her doctoral degree from the University of Massachusetts.
Sylvia Bartel, RPh, MHP, CPEL
Senior Vice President of Pharmacy, Chief Pharmacy Officer
Sylvia Bartel, RPh, MHP, CPEL, is Senior Vice President of Pharmacy and Chief Pharmacy Officer. She has worked at Dana-Farber for 30 years in various pharmacy roles and has contributed to transformative initiatives, including opening regional campuses, implementing an outpatient specialty pharmacy program, establishing the advanced practice clinical pharmacist role, and expanding staff and roles aligned with the Institute's growth.
Bartel's interests include strategic clinical and operational pharmacy initiatives, exploring AI-driven solutions to enhance pharmacy practice, optimizing financial performance, streamlining operations, and improving system safety across the medication use process. Bartel earned her pharmacy degree from the University of Wisconsin School of Pharmacy and her Master of Health Professions from Northeastern University, Bouvé College of Pharmacy and Health Sciences. She also completed a postgraduate pharmacy residency at the National Institutes of Health.
Lisa R. Diller, MD
Vice-Chair, Department of Pediatric Oncology
Lisa R. Diller, MD, serves as Vice Chair for the Department of Pediatric Oncology at Dana-Farber and Medical Director of the David B. Perini, Jr. Quality of Life Clinic for Childhood Cancer Survivors. She conducts research on the late effects of childhood cancer treatment and genetic cancer predispositions in childhood, and her clinical work focuses on pediatric solid tumors.
Diller received her bachelor’s degree from Harvard University and earned her Doctor of Medicine from the University of California at San Diego.
Michael Hassett, MD, MPH
Chief Quality Officer
Michael Hassett, MD, MPH, is the Chief Quality Officer at Dana-Farber. Since joining Dana-Farber in 2005, he has worked as a medical oncologist in the Breast Oncology Program. He is also a health systems researcher who focuses on identifying gaps in cancer care and on developing solutions that improve outcomes, reduce disparities, and maximize quality of life for patients.
Hassett received his MD from the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, and his MPH from the Harvard T.H. Chan School of Public Health. After serving as a Resident and Chief Resident in Internal Medicine at the University of Rochester, New York, he completed a fellowship in medical oncology at Dana-Farber and Mass General Brigham Hospital.
Christopher S. Lathan, MD, MS, MPH
Chief Clinical Access Officer
Christopher S. Lathan, MD, MS, MPH, is Dana-Farber's Chief Clinical Access Officer, Associate Chief Medical Officer, and Director for Dana-Farber's Regional Campuses. He is also Associate Professor of Medicine at Harvard Medical School.
Lathan’s work focuses on addressing the impact of systemic barriers, expanding access to high-quality cancer diagnostics, and providing treatments to communities most burdened with the disease. A clinical oncologist specializing in lung cancer, Lathan is founding director of Dana-Farber's Cancer Care Access Program, a clinical outreach program that supports cancer diagnosis and treatment for patients at Federally Qualified Health Centers and provides community-focused navigation for newly diagnosed patients from local neighborhoods. He and his team works to broaden pathways to early diagnosis and ensure the equitable distribution of new treatments, thereby bridging the gap between cancer therapeutics research and clinical care through innovative, patient-centered interventions in the health care delivery system.
Andrew E. Place, MD, PhD
Vice President, Pediatric Chief Medical Officer, Department of Pediatric Oncology
Andrew E. Place, MD, PhD, is Vice President and Chief Medical Officer for Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. He oversees clinical programs that provide care to children with cancer and to patients in the bone marrow transplant program at both Boston Children’s Hospital (BCH) and Dana-Farber. As a physician-scientist, Place specializes in treating pediatric leukemia and lymphoma. His research investigates novel therapies for children with high-risk leukemias through the design and implementation of clinical trials.
Place is an internationally recognized clinical trialist who serves in leadership roles within several national/international consortia including the Dana-Farber Childhood Acute Lymphoblastic Leukemia Consortium, the Therapeutic Advances in Childhood Leukemia Consortium, and the Children’s Oncology Group. He earned both his MD and PhD at Dartmouth College prior to completing his Pediatric Residency and Pediatric Hematology/Oncology fellowship at BCH and Dana-Farber.
Chandrajit P. Raut, MD, MSc
Surgeon-in-Chief
Chandrajit P. Raut, MD, MSc, is Surgeon-in-Chief for Dana-Farber. In this role, he oversees the oncologic surgical staff and programs through the Institute’s collaboration with Brigham and Women’s Hospital (BWH). Raut is also Chief of the Division of Surgical Oncology. Specializing in the multidisciplinary care of patients with soft tissue sarcoma, he serves as Surgery Director for the Sarcoma Center at Dana-Farber. He is also a Professor of Surgery at Harvard Medical School (HMS) and the inaugural Distinguished Chair for Cancer Care at BWH.
Raut's research focuses on multimodal strategies to reduce rates of local recurrence for patients with sarcoma. He received his BA and BS from Stanford University, his MSc from the University of Oxford in England, and his MD from HMS. He completed his residency in general surgery at Massachusetts General Hospital and a fellowship in surgical oncology at MD Anderson Cancer Center.
Martha Wadleigh, MD
Medical Director, Inpatient Oncology
Martha Wadleigh, MD, is Medical Director for Inpatient Oncology at Dana-Farber. In 2004, she joined the Institute's Adult Leukemia Program treatment team.
Wadleigh received her MD from Duke University School of Medicine. She completed postgraduate training in internal medicine at Duke University Medical Center, followed by a fellowship in medical oncology and hematology at Dana-Farber and Brigham and Women’s Hospital.
Andrew J. Wagner, MD, PhD
Medical Director, Ambulatory Oncology
Andrew J. Wagner, MD, PhD, is the Deputy Chief Medical Officer and Medical Director of Adult Ambulatory Oncology at Dana-Farber. Wagner has been a medical oncologist at the Institute for more than 20 years. He is also a Senior Physician in the Department of Medical Oncology, a translational researcher in the Sarcoma Center, and an Associate Professor of Medicine at Harvard Medical School.
Wagner focuses on treating patients with sarcoma and conducts translational research and clinical studies to identify new targets and treatments. He earned his MD and PhD in biochemistry and molecular biology from the University of Chicago Pritzker School of Medicine. He completed his internal medicine training at Brigham and Women’s Hospital, followed by a fellowship in hematology and medical oncology at Dana-Farber, Brigham and Women’s Hospital, and Massachusetts General Hospital.
David A. Williams, MD
Associate Chair, Department of Pediatric Oncology
David A. Williams, MD, is Associate Chair for the Department of Pediatric Oncology at Dana-Farber and Chief of Hematology/Oncology and Director of Clinical and Translational Research at Boston Children’s Hospital. He also directs the Pediatric Hematology/Oncology Fellowship Training Program at Dana-Farber/Boston Children’s Hospital.
Williams has served on multiple NIH studies, including the Loan Repayment Study Section for Pediatrics, NCI Parent Committee for Comprehensive Cancer Centers, Recombinant DNA Advisory Committee, and NIH Gene Therapy Safety Advisory Board. He is a member of the National Academy of Sciences and has published over 250 peer-reviewed manuscripts, more than 100 invited reviews, and numerous textbook chapters. He is active in gene therapy trials for blood, immune, and neurological diseases. A past President of the American Society of Hematology, he has trained over 45 fellows and numerous residents and medical students.
Meet More of Our Leaders
Operations and Administration Leadership
This team ensures that Dana-Farber runs smoothly, efficiently, and in alignment with our strategic objectives.
Department Chairs and Academic Leadership
Our Department Chairs and Academic Leadership team fosters an environment of learning and innovation at Dana-Farber.
Dana-Farber Leadership
Our team of prominent clinicians, researchers, and business leaders is committed to innovation and patient-centered care.